Screener
Travere Therapeutics, Inc. TVTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses | (20,900) | (9,538) |
| Deferred revenue | — | (1,349) |
| Other current and non-current liabilities | 1,940 | 709 |
| Net cash used in operating activities | (40,366) | (42,194) |
| Cash Flows From Investing Activities: | ||
| Proceeds from the sale and maturity of marketable debt securities | 48,782 | 53,157 |
| Purchase of marketable debt securities | (5,055) | — |
| Purchase of intangible assets | (22,178) | (11,784) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s operating cash flow?
- Travere Therapeutics, Inc. (TVTX) reported operating cash flow of -$40.37M in Q1 2026.
- How has Travere Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Travere Therapeutics, Inc.'s operating cash flow increased by 4.3% year-over-year, from -$42.19M to -$40.37M.
- What is the long-term trend for Travere Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2022 to 2024), Travere Therapeutics, Inc.'s operating cash flow has grown at a 12.9% compound annual growth rate (CAGR), from -$186.29M to -$237.48M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Travere Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude